Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.49 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | PIP5K1B | O14986 | 1/20 | 0.44 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151491 | 0.84 | MAPK10 (0.62) | MAPK10MAPK8MAPK14EGFRPIP5K1B | |
| SCHEMBL13675601 | 0.83 | EGFR (0.53) | MAPK10GSK3BSYKEGFRPIK3CA | |
| SCHEMBL13675603 | 0.82 | TRPV1 (0.47) | MAPK10GSK3BKIF11 | |
| SCHEMBL13675609 | 0.79 | TRPV1 (0.72) | MAPK10GSK3B | |
| SCHEMBL13675604 | 0.79 | GAK (0.56) | MAPK10EGFRPIK3CA | |
| SCHEMBL1013229 | 0.78 | TRPV1 (0.65) | — | |
| SCHEMBL1518963 | 0.78 | MAPK10 (0.59) | MAPK10MAPK8MAPK14PIP5K1BPIP5K1C | |
| SCHEMBL12367613 | 0.77 | ALDH1A1 (0.54) | KIF11 | |
| SCHEMBL13133429 | 0.77 | ALDH1A1 (0.54) | KIF11 | |
| SCHEMBL4002053 | 0.77 | TRPV1 (0.70) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | MAPK10 853/4885MAPK8 1179/4885GSK3B 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.